Related Experiment Video
Updated: Jan 6, 2026
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Mining tumor and surrounding tissue information using artificial intelligence to predict responses to EGFR-targeted
Xingping Zhang1,2,3, Yuxin He1, TianXiang Rao1
1School of Medical Information Engineering, Gannan Medical University, Ganzhou, 341000, China.
Purpose:
In cancer therapy, tumor cell heterogeneity and dynamics influence gene sequencing and immunohistochemical staining. Importantly, patients treated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have not demonstrated a favorable long-term prognosis. Therefore, this study proposes an integrated framework for artificial intelligence (IFAI) to explore new molecular detection methods.
Materials And Methods:
Our study integrated data from 506 non-small cell lung cancer (NSCLC) patients across three institutions in China and the USA. To fuse radiomics scores and deep network features from both tumors and surrounding tissues, we developed the IFAI with an attention-based DenseNet 121 as the backbone network. We also explored the synergy between IFAI and clinical factors (IFAI-C). Additionally, we gained further insights into the biological mechanisms of IFAI by analyzing patient RNA sequencing data.
Results:
In independent test data, the IFAI-C demonstrated notable predictive performance, boasting an area under the curve of 0.912 for EGFR, 0.911 for exon 19 deletion (19Del), 0.905 for exon 21 mutation (L858R), 0.911 for T790M, and 0.904 for programmed cell death protein 1 (PD-1) or its ligand 1 (PD-L1). This capability is a crucial complement to traditional methods like gene sequencing and immunohistochemistry. Our analysis revealed that radiomics scores and deep network features in IFAI were significantly associated with EGFR genotypes, drug resistance mutations, and immune molecule expression. Furthermore, these features displayed robust connections with multiple genotypes associated with drug resistance and cancer progression mechanisms.
Conclusion:
IFAI-C introduces a novel method with performance advantages, accompanied by biological analyses demonstrating the extraction of genotypic and immunomolecular information from both tumors and surrounding tissues. This discovery holds potential value in guiding therapeutic decisions for lung cancer.
Insights
An artificial intelligence framework (IFAI-C) accurately predicts lung cancer mutations and immune markers, outperforming traditional methods. This AI approach aids in guiding therapeutic decisions for non-small cell lung cancer patients.
Area of Science:
- Oncology
- Artificial Intelligence
- Radiomics
Background:
- Tumor heterogeneity impacts cancer therapy efficacy, particularly for patients on EGFR-tyrosine kinase inhibitors (TKIs).
- Existing diagnostic methods like gene sequencing and immunohistochemistry have limitations in capturing tumor dynamics.
- There is a need for advanced molecular detection methods in non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To develop an integrated artificial intelligence framework (IFAI) for novel molecular detection in NSCLC.
- To explore the synergy between IFAI and clinical factors (IFAI-C) for enhanced predictive performance.
- To investigate the biological mechanisms underlying IFAI's predictions.
Main Methods:
- Integrated data from 506 NSCLC patients across China and the USA.
- Developed IFAI using an attention-based DenseNet 121 to fuse radiomics and deep network features.
- Analyzed RNA sequencing data to understand IFAI's biological insights.
Main Results:
- IFAI-C achieved high predictive performance (AUC > 0.90) for EGFR mutations (19Del, L858R, T790M) and PD-1/PD-L1 expression.
- Radiomics and deep network features in IFAI significantly correlated with EGFR genotypes and drug resistance mechanisms.
- IFAI features showed robust associations with genotypes linked to drug resistance and cancer progression.
Conclusions:
- IFAI-C offers a novel, high-performance method for molecular detection in NSCLC.
- Biological analyses confirm IFAI extracts genotypic and immunomolecular information from tumor and surrounding tissues.
- This AI-driven approach shows potential for guiding lung cancer treatment decisions.
More Related Videos
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023